Cost–effectiveness analysis of inhaled corticosteroids in asthma: a review of the analytical standards  by PERSSON, U & GHATNEKAR, O
Vol.97 (2003) 1^11REVIEW
Cost^e¡ectiveness analysis of inhaled
corticosteroids in asthma: a review of the analytical
standards
U.PERSSON AND O.GHATNEKAR
IHE,The Swedish Institute for Health Economics, Lund, Sweden
Abstract Purpose:To determine whether published cost^effectiveness studies on inhaled corticosteroids (ICS) in
asthma adhered to basic analytical standards as defined in health economic textbooks and in guidelines assessing and
comparingefficacyand safety.Methods:Original cost^effectiveness studiespublishedbetween1990 and 2000 in general
medical or economic journalswere reviewed to assess the adherence to five fundamentalmethodological principles: (1)
design of the study, (2) choice of perspective and corresponding costs, (3) choice of outcomemeasure, (4) marginal cost
analysis, and (5) sensitivity analysis and discussion about external validity.For each principle, the studieswere ranked as
high, mediumor lowquality.Results:Mostofthe18 studies includedwere rankedmediumonthe firsttwoprinciples.The
studies adhered to a higherdegree to the remaining three principles.Only three studieswerehighranked in all fiveprin-
ciples.The numberof principles fulfilled increased over time.Studies comparing pharmaceuticalproducts from compet-
ing companies were typically short-term studies, designed for other purposes than health economic analyses, and, in
general, did not use therapeutically equivalent dosing.Conclusions: Attention should be drawn to the study design, the
weak correspondence between perspective and costs, and especially to the impact of bias in health economic results
when comparingdifferentdoses of ICSs.r2002 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2002.1405, available online at http://www.sciencedirect.comINTRODUCTION
Cost^ e¡ectiveness analysis is currently an accepted ana-
lytical technique to establish the relationship between
costs and e¡ectiveness of a particular intervention. In
pharmaco-economics, cost^ e¡ectiveness analysis is
used to assess if one drug (or combination of drugs) is
more cost-e¡ective than another under similar circum-
stances. Pharmacoeconomic studies are often an impor-
tant component in price-regulation and reimbursement
decisions, as well as in drug formulary listings and mar-
keting. Hence, several countries have developed guide-
lines for performing such studies [see (1) for an
overview].
Inhaled corticosteroids (ICS) were introduced in 1972
andwere at ¢rst limited to the treatmentof severe asth-
ma. In the second half of the 1980s, increased under-
standing that asthma is an in£ammatory disease andReceived16 January 2002, accepted in revised form18 June 2002.
Correspondence should be addressed to:Dr.Ulf Persson, IHE,The
Swedish Institute for Health Economics, Box 2127, Se-220 02 Lund,
Sweden.Fax: +46-46-12-16-04; E-mail: up@ihe.sethat ICS have an anti-in£ammatory e¡ect developed.
More recently, studies demonstrated that ICS therapy
reduces the risk of asthma-related hospitalisation and
outpatient visits (2^4).
Published review articles suggest that the acquisition
cost of ICS can be o¡set by a reduction in other health-
care costs (5,6). However, few reviews examined the
methodologies used in the health economic studies on
asthma, which is important in order to give decision-ma-
kers in health service assistance in interpreting results.
One exception was Buxton (7), who concluded that
scarcity of cost^ e¡ectiveness studies partly was due to
the di⁄culty of de¢ning an outcome measure that cap-
tures the multidimensional e¡ects of respiratory inter-
ventions. The National Asthma Education and
Prevention ProgramWorkingGroup conducted a review
of the literature on cost^ e¡ectiveness of asthma patient
education programmes, pharmaceutical therapy, and a
variety of alternative and adjunct interventions (8).They
revealed many shortcomings and a lack of standard ap-
proach to evaluate the cost^ e¡ectiveness of medical
technologies in asthma.
2 RESPIRATORYMEDICINEAlthough guidelines exist for cost^ e¡ectiveness stu-
dies, few attempts havebeenmade to evaluate the analy-
tical standards and adherence to basic cost^
e¡ectiveness principles in the area of asthma treatment.
The purpose of this study was to examine whether
published cost^ e¡ectiveness studies on ICS in asthma,
publishedup to theyear 2000, adhered tobasic analytical
standards as de¢ned in economic textbooks and guide-
lines.
METHODS
Article selection
Articles published 1990^2000 were drawn from a Med-
line and Embase literature search using15 keywords* re-
lated to ICS treatment for asthma. To simplify the
analysis of this studyonly full-length (no abstracts), origi-
nal cost^ e¡ectiveness studiesbased ondata fromrando-
mised clinical trials (RCTs) were considered. Cost of
illness and cost minimisation studies, review articles,
and studies on e⁄cacy without any attempt to provide
information on costs were excluded.
Methodological review
To identify principles appropriate for cost^ e¡ectiveness
analysis and economic evaluation of healthcare practices
in general, a literature review of guidelines and health
economic textbooks was performed (9^14). Variables
such as the clinical trial design, choice of comparator,
cost and perspectives, results presentation and sensitiv-
ity, are evaluated. However, the therapeutic e¡ect of in-
haled agents is in£uenced by a number of factors, not
only the pharmacological potency, but also the doses
used, the treatment duration and the amount reaching
the airways and lungs, the latter depending on the type
of inhaler used. Hence, a review of guidelines on how to
assess and compare the underlying ICS e⁄cacy and
safety data (8,15^17) complements the economic guide-
lines.
On the basis of this literature, ¢ve principles thought
to comprise a high standard that cost^ e¡ectiveness stu-
dies should be expected to follow were identi¢ed: (1) de-
sign of the study; (2) choice of perspective and
corresponding costs; (3) choice of outcomemeasure; (4)
description of the costing methods and marginal cost
analysis; and (5) sensitivity analysis and discussion of ex-
ternal validity. As each principle not necessarily has the
same weight, we present the results of each principle in
a disaggregate form.*Azmacort, beclomethasone, beclomethasone dipropionate,
budesonide, cost, cost^ e¡ectiveness, cost utility, economics, Flixotide,
£uticasone, £uticasone propionate, health, pharmacoeconomics,
Pulmicort and triamcinolone acetonide.Design of the study
Adherence to good practice in designing trials for inves-
tigating alternative treatments of asthma was evaluated
on four basic criteria.First, the study should be designed
as a parallel- group RCTandnot as, e.g., a crossover trial
in which subjects serve as their own control.The cross-
over design is less accepted for asthma trials comparing
ICS because therapeutic e¡ects of variable persistence
may spill over from the ¢rst treatment to the adminis-
tration of the second (16). Second, to account fully for
the costs and e¡ects of an intervention, results should
be reported for the entire sample of recruited patients,
i.e., an intention-to-treat analysis (8). In addition, costs
included should not be driven by the trial itself. Hence,
the economic analysis should at least have been planned
and coordinatedwith the RCT, i.e., it should have had an
impact on the study design.Third, as asthma is a chronic
disease, the follow-up period should be long enough to
allow assessment of e¡ectiveness, possible dropouts
and costs (8).We required a study period of at least 6
months, the same requirement as in an evaluation by
the Swedish Council on Technology Assessment in
Health Care (18).
Finally, the choice of dosage in£uences not only clinical
andhealth outcomes, but also has an impacton the cost^
e¡ectiveness ratio. Although a doubling of doses may
have a modest e¡ect on clinical or health outcomes, it
nevertheless doubles themedication cost. As drug costs
normally represent most healthcare costs in mild and
moderate asthma (19,20), cost^ e¡ectiveness ratios could
be heavily biasedwhen inappropriate dose combinations
are used. It is beyond the scope of this study to fully eval-
uate the appropriate comparison of dose combinations.
However, we have used a de¢nition of therapeutically
equivalent dose between £uticasone proprionate (FP)
and budesonide (BUD) if the FP:BUD dose ratio was 1:2
or less when a pressurisedmetered dose inhaler (pMDI)
was used. If the drugs were inhaled through a dry-pow-
der inhaler (DPI), e.g.,Diskhaler orTurbuhaler, the corre-
sponding equivalent dose ratio was de¢ned as 1:1
(15,21,22).Dosages in studies comparing another ICSwith
BUD or FP were accepted since we were unable to ¢nd
similar dose equivalents.
If all four criteria were ful¢lled we ranked the study
high. Consequently, a study was ranked low/medium if
neither/some of the criteria was/weremet.
Choice of perspective and corresponding
costs
Cost^ e¡ectiveness analysis can be undertaken from a
number of di¡erent perspectives. The societal perspec-
tive is themost comprehensive and incorporates, in the-
ory, all costs and all health e¡ects regardless of who
incurs the costs and who obtains the bene¢ts. Other
w‘‘Dominant’’ indicates an alternative that is both less costly and
produces a better outcome than the other alternative(s).
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ment, healthcare institutions (e.g., hospital or clinic),
third-party payer, and patient and family. The choice of
perspective has important methodological rami¢ca-
tions, and, as the included cost items di¡er between per-
spectives, the cost^ e¡ectiveness ratios will changewith
the perspective chosen.
We demanded a high ranked study to make it obvious
what perspective was chosen and that costs included in
the analyses corresponded to the perspective. If costs
did not correspond to the perspective chosen, or if the
perspective was not discernible, the study was ranked
medium and low, respectively.
Choice of outcomemeasure
It is often recommended that choice of e¡ectiveness
measure should relate to a ¢nal health outcome such as
life-years saved or healthy days gained (9).The numerous
outcome measures for asthma can roughly be cate-
gorised into ¢ve key outcomes (8): clinical and symptom
measures (exacerbations, symptom-free days, etc.), phy-
siological measures [surrogate endpoints, e.g., peak ex-
piratory £ow (PEF)], quality-of-life measures, patient
management (behavioural change and compliance), and
health services utilisation, e.g., the number of hospital
visits.
Surrogate endpoints must be explicitly related to
some health bene¢t since it is health per se that should
be maximised. In one in£uential article on outcomes
measure in health economic analysis, it was concluded
that surrogate endpoints cannot be recommended in
cost^ e¡ectiveness analysis (13), which corresponds to
the statement in the consensus report from the Eur-
opean experts on methodological issues. According to
this document, ‘‘surrogate endpoints are not recom-
mended as e¡ectivenessmeasures of cost^ e¡ectiveness
analyses unless (a) they have a clear meaning to decision
makers, (b) they are unambiguously correlated with
health status and capture all the relevant di¡erential ef-
fects on the outcomes of the options compared’’ (14).
This review distinguished between physiological (sur-
rogate) endpoints and (non-surrogate) health-related
outcomes without regarding the appropriateness of the
measures used. To receive a high rank, a health-related
outcomemeasure shouldbereported. If onlyother types
of outcomes were reported, the study was ranked low
(this principle has nomedium rank).
Description of the costingmethods and
marginal cost analysis
Costs should ideally re£ect the value of the input in its
best alternative use. Unit prices for inputs and medical
procedures do not necessarily re£ect theminimum costas they couldbe based on average costs, and notpatient-
speci¢c costs. Another way is to use charges or fees,
e.g., for hospital admissions for studies in the United
States, but the usual approach is to use cost-to-charge
ratio to convert billing information into economic cost
estimates (10). A third alternative, often used in Europe,
is to use accounting costs, e.g., for a physician visit. A
fourth approach is to conduct a whole cost estimation,
based on information about inputs such as salary cost
per time unit, cost of facilities, administration, etc.
When comparing two healthcare programmes, the in-
cremental cost^ e¡ectiveness ratios (ICER) is the appro-
priate measure (9,10,14,23). When choosing between
di¡erent technologies, the ICER tells us cost per unit of
bene¢t when switching from one treatment to another,
e.g., incremental cost per symptom-free day gained.
Average cost, on the other hand, re£ects the cost per
bene¢t independent of other treatments.
To be ranked high, we required that a study present
su⁄cient information for assessing the costing methods
and that the ICER approach was used in case one alter-
native was not dominantw. If only one of these criteria
was ful¢lled, the study was rankedmedium, and if none
was ful¢lled, the study was ranked low.
Sensitivity analysis anddiscussionof external
validity
Conventional statistical methods are only applicable if
the data are sampled. In cost^ e¡ectiveness studies, data
are often sampled for some items of resource use, e.g.,
number of physician visits, days in hospitals, etc. How-
ever, costs are often generated from other sources. Sen-
sitivity analysis is therefore the primary method for
allowing for uncertainty in economic evaluations (9). By
varying a single ormultiple (more thorough) variables at
a time, the sensitivity of the results is studied. Further-
more, data fromRCTsmay have a lowdegree of external
validity due to a strict research protocol. Therefore, a
discussion on the ability to generalise the results to the
real-world setting is important.
Both a discussion about the external validity and sen-
sitivity analysis (regardless of single- or multi-dimen-
sional) were necessary to achieve a high rank. If only
one or none of these was reported, the study was
rankedmedium or low, respectively.
Analysis
We ranked the ¢ve principles as high, medium or low
based on the aforementioned criteria. For each of the
¢ve principles, the articles were then compared by type
of journal publication, whether the study compared two
TABLE 1. Numberof studies rankedhigh, mediumandlow for eachprinciple
High Medium Low Total
Design 6 8 4 18
Perspective and correspondingcosts 6 8 4 18
Outcomemeasure 15 ^ 3 18
Costingmethods andmarginal analysis 11 6 1 18
Sensitivity analysis and externalvaliditydiscussion 9 6 3 18
}
4 RESPIRATORYMEDICINEor more competing products, by the pharmaceutical
company sponsoring the study, and by the year of
publication (old: 1993^1996; new: 1997^2000). These
comparisons were chosen to reveal methodological dif-
ferences in medical and non-medical journals, in studies
comparing doses of the sameproduct or competing pro-
ducts, whether the stakeholders could have had an im-
pact, and if there has been a growing awareness for
health economic methods over time.
RESULTS
Article selection
The literature search generated 194 matching articles
but included many articles without any cost^e¡ective-
ness analysis and reviews; therefore, only 46 articles
were further considered. Of these, another 30 papers
were rejected as they were descriptive cost of illness
analyses, reviews or meta-analyses, or did not include a
comparison of alternative treatments. Another two ar-
ticleswere found in the articles’reference lists.Hence,18
articles were included in this analysis (see reference list).
Eight studies evaluated a single ICS: two compared
BUD vs. usual carewithout ICS, four compared di¡erent
doses of BUD, one compared di¡erent doses of FP and
one compared FP vs. a combination of FP and a
b2-agonist. In one study, a combination of b2-agonist/
anticholineric therapy was comparedwith a combination
ofb2-agonist/ICS therapy (classi¢ed in this review as com-
peting products). In the other nine studies, two ICSwere
compared. Six of these studies compared FP vs. BUD; in
four of them a DPI was used as the inhaler device, and, in
the other two studies, two di¡erent inhaler devices were
used, e.g., pMDIvs.DPI.Theremaining three studies com-
pared FP vs. sodium cromoglycate, FP vs. triamcinolone
acetonide and FP vs. £unisolide, respectively.
Ten articles were found in economic journals, and
eight were published in medical journals. Six articles
were sponsored by AstraZeneca (AZ) and 10 by Glaxo
Wellcome (GW). The remaining two studies received
grants from several sources.zzSponsors were: the Netherlands’ Health Research Promotion
Program (SGO), the Dutch Asthma Foundation,Glaxo, Astra
Pharmaceuticals and Boehringer Ingelheim.For the two principles, design and costs correspond-
ing to theperspective chosen,most studieswere ranked
medium (Table 1). Short length of study (11 studies) and
design mainly for other purposes than economic evalua-
tion (10 studies) reduced the scores. One study had a
cross over design. For the remaining three principles,
the studies adhered in a higher degree to the require-
ments.
Only three studies were highly ranked in all ¢ve prin-
ciples (Table 2).One study was ranked high on four prin-
ciples and medium on one principle. Studies comparing
competing products were to a higher degree sponsored
by GW, were publishedmore recently and had a shorter
study period than the non-competing product studies.
Older studieswere predominantly published in econom-
ic journals.
Design
The median length of the underlying RCTs were 3
months (mean length, 7.2 months; range, 1^30 months),
and only seven studies had a study period of at least 6
months. All articles provided information on dosing, but
four of the 10 studies comparing alternative ICS did not
ful¢l the requirements for therapeutically equivalent
dosing.}
Ten studies were originally designed for purposes
other thaneconomic analysis, of which sevenwere found
in the competing-drugs studies.Only one study was de-
signed for economic analysis. Studies published in medi-
cal journals were based more often on RCTs with a
longer study period and studies not comparing compet-
ing drugs ful¢lled the criteria of equivalent dosing to a
higher degree (Fig.1).
Perspective chosen and corresponding costs
Fourteen studies stated a national healthcare system,
societal or third-party payer perspective. In theOf six studies comparing FP andBUD, onlyone compared the drugs on
a1:1dose ratio (400mg), whereas the other ¢ve had doses varying
between1:2 (except for one subgroupwhere the relationshipwas1:1) to
1:3.2.
TABLE 2. Studies highly, mediumandlowranked for eachprinciple
Studynumber
A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 A13 A14 A15 A16 A17 A18
Yearof publication 1993 1993 1993 1995 1995 1996 1996 1996 1997 1997 1998 1998 1998 1999 1999 1999 2000 2000
Economic Journal 1 1 1 1 0 1 0 1 1 0 0 0 1 1 0 1 0 0
Sponsorship AZ AZ n.a. GW n.a. GW AZ AZ AZ GW GW GW GW GW AZ GW GW GW
Competingdrugs 0 0 0 1 1 1 0 1 0 1 1 0 1 1 0 0 1 1
Length of study (months) 3 6 22 2 30 2 4 2 12 1 2 24 1.5 1.5-2 1.5 3 6 6
1.Design Med High High Low High Med Med Med High Low Low High Low Med Med Med Med High
Parallel-group RCT 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1
Length of studyX6 months 0 1 1 0 1 0 0 0 1 0 0 1 0 0 0 0 1 1
Equivalentdosing 1 1 1 0 1 1 1 1 1 0 1 1 0 1 1 1 0 1
Economic impacton design 0 1 1 0 1 0 0 0 1 0 0 1 0 0 0 1 1 1
2.Perspective Low High Med Med High Med High Low High Low Low High Med Med Med Med Med High
Perspective stated 0 1 1 1 1 1 1 0 1 0 0 1 1 1 1 1 1 1
Costs correspond 0 1 0 0 1 0 1 0 1 0 0 1 0 0 0 0 0 1
3.Outcomemeasure High High High Low High High High High High Low High Low High High High High High High
4.Costing presentation Med High High Med High Low Med Med High Med High Med High High High High High High
Costingmethod 0 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1
ICERordominant 1 1 1 0 1 0 0 0 1 0 1 0 1 1 1 1 1 1
5.Validation Low Low High Med High Med Low High High Med Med Med High High Med High High High
Sensitivity analysis 0 0 1 1 1 1 0 1 1 1 0 0 1 1 1 1 1 1
Externalvalidity 0 0 1 0 1 0 0 1 1 0 1 1 1 1 0 1 1 1
Note:1=yes,0=no, n.a.=not applicable.
Abbreviation: ICER=incremental cost^e¡ectiveness ratio; AZ=AstraZeneca;GW=GlaxoWellcome;RCT=randomised clinical trial.
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FIG. 1. Comparing the proportion of studies rankedhigh, mediumand lowunder the criteria fordesign.
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FIG. 2. Comparing the proportion of studies rankedhigh, mediumandlowunder the criteria of perspective and costs correspond-
ing to perspective chosen.
6 RESPIRATORYMEDICINEremaining four studies, the perspective was unknown.
Overall, only six of the studies managed to cost the
resource consumption in accordancewith the perspectivetaken, which drives the results depicted in Fig. 2.This de¢-
ciency was mainly due to a lack of information about
whether adjustments for patient co-paymentsweremade.
CORTICOSTEROIDS INASTHMA 7The competing-drugs group attained the lowest
scores due to non-explicit perspective and non-corre-
sponding costs.
Outcomemeasure
In the 18 articles reviewed, 16 di¡erent outcome mea-
sures (11 surrogate and ¢ve health-related outcomes)
were used, of which eight were used in more than one
article. The most frequently used measure was symp-
tom-free days (11articles). Another threemeasureswere
used in three or more articles.The de¢nition of a symp-
tom-free day varied between articles (and study arms in
one article), as did the de¢nition of ‘‘success’’ among the
surrogate endpoints (e.g., PEF 490% or PEFX95% of
predicted).
Three articles did not present any health-related out-
comes, whereas two studies reported such measures
only. Hence, the reviewed articles adhered well to the
standards (Fig. 3).
Marginal costing analysis
Information on costing methods was provided in all but
two studies, and ¢ve articlespresented average cost ana-
lysis only.Overall, the costing method and the marginal
analysis adhered well to what could be expected from a
cost^ e¡ectiveness study.Low
Outco
13%
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25%
10%
88%
80%
75%
90%
0%
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Old (n=8) New (n=10) Medical J
(n=8)
Economic J
(n=10)
FIG. 3. Comparing the proportion of studies ranked high, mediu
ranknot available).Newer articles performed better than older articles
due to a more detailed presentation of costing methods
and of incremental cost^ e¡ectiveness ratios (Fig. 4). In
four studies comparing competing products, only aver-
age cost^ e¡ectiveness ratios were presented.
Sensitivity analysis and external validity
discussion
Sensitivity analysis and discussion of external validity
were reported in13 and11of the18 articles, respectively.
Newer articles, articles comparing competing products
and GW-sponsored articles discuss the external validity
of the resultsmore frequently than older studies (Fig. 5).
DISCUSSION
Eighteen original health economic studies on inhaled ICS
for treatment of asthma were evaluated according to
analytical standards. Evaluation was based on confor-
mance with ¢ve basic principles commonly found in the
health economic literature and speci¢c guidelines on
how to scienti¢cally assess and compare ICS e⁄cacy
and safety. This study does not claim to be comprehen-
sive, as it is speci¢cally limited to original cost^e¡ective-
ness studies based on RCT. However, with slight
modi¢cations of the criteria, the principles can be ap-
plied to evaluations of other pharmaceutical pro-
grammes.High
me Measure
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Costing Methods and Marginal Analysis
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FIG. 4. Comparing theproportionof studiesrankedhigh,mediumandlowunder the criteriaofcostingmethodschosenandmargin-
al analysis performed.
Sensitivity Analysis and External Validity
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FIG. 5. Comparing theproportionof studiesrankedhigh, mediumandlow for the criteria of sensitivityanalysis anddiscussion about
externalvalidity.
8 RESPIRATORYMEDICINEIn order to avoid the complex concept of quality we
have used simply binary (high^low) method of analysis.
We have not considered whether the criteria/principles
are ‘‘very well’’ or ‘‘barely’’ ful¢lled. Hence, great varia-tion prevails within our grading. No ranking or weights
has been assigned to the principles. This methodology
leaves room for more through quality analysis, which is
beyond the aim of this study. However, we believe this
Benefit
Dose
Drug A
Drug B
x y
FIG. 6. Hypothetical dose^response curves for two pharma-
ceutical compounds.
CORTICOSTEROIDS INASTHMA 9analysis brings forward some potential problems and ca-
veats to bear in mind in spite of the limited number of
studie cost^ e¡ectiveness articles.
In four of the principles for cost^ e¡ectiveness analy-
sis, principles 2^5, the ranking of the studies increased
over time. This could re£ect the greater awareness of
the common principles for conducting health economic
analyses among authors and/or reviewers.
The most frequently occurring shortcoming was the
lack of correspondence between costs and perspective.
For example, some studies stated a third-party payer
perspectivebut includedpatient co-payments in the cost
for pharmaceuticals.Other examples showed that even if
a national healthcare perspective was chosen, the analy-
sis did not include costs other than pharmaceuticals. In
some studies, therewas not even an attempt to estimate
costs for health care other than medicines. Including
non-relevant (or excluding relevant) costs drives the
cost^ e¡ectiveness ratio and can bias the results.
Design was another reason for a low ranking of sev-
eral studies.With a median study period of 3 months, it
was uncertain whether the full clinical e¡ect was at-
tained and if relatively rare events such as hospitalisa-
tions were fully captured. An interesting observation
was the correlation between low-scored studies relying
on relatively short-term RCTs and low-scored studies on
competing therapies.These short-term studieswere not
designed for economic purposes, and in neither of these
studies did the costs correspond to the stated perspec-
tive.
Another serious design problem, and until recently a
less noticed issue (17), was the variation in dose ratios
between FP and BUD (varied between 1:1 and 1:3.2). In
the following hypothetical example, we discuss the issue
of comparing appropriate doseswhen evaluating alterna-
tive ICS.
Assume that drugs A and B are priced the same per
weight and that they have di¡erent dose^response
curves in that drug A reaches a plateau earlier than drug
B (Fig. 6).The two compounds are evaluated at a dose re-
lationship of1:1, e.g., at dose x. Drug Awould not be sig-
ni¢cantly more e¡ective than drug B, and the costs for
the two alternative medicines would be the same. As a
second case, assume that drug Awould be administered
at dose x, whereas drug B will be administered at dose
y=2x, i.e., a double dose. A comparison of the twodrugs
at a dose relationship of1:2 would result in a similar ben-
e¢t for both treatment groups. However, as the drugs
are priced exactly the same, the costs for the patient
group receiving drug B will be twice as high as the costs
for the patient group receiving drug A.
A cost^ e¡ectiveness analysis using a1:2 dose relation-
ship would then result in a disadvantage for drug B as a
signi¢cant di¡erence in drug costs is compared with a
non-signi¢cant di¡erence in bene¢ts.On the other hand,
a cost^ e¡ectiveness analysis using a1:1dose relationshipwould result in a more favourable outcome for drug B as
the non-signi¢cant di¡erence in bene¢ts is attained at
identical drug costs.The implication is that the choice of
doses based on studies evaluating e⁄cacy and safety
could result in biases in cost^ e¡ectiveness studies.
The increased reporting of health outcomes should
not be a goal per se. It is important that these measures
(both surrogate and health-related) are standardised to
enhance comparability between studies (8,23). If symp-
tom- and episode-free days areused, it is imperative that
the same de¢nition applies in all study-arms and that the
scale is uniform. In addition, the lack of outcome unifor-
mity infringes on the credibility through the impression
that authors choose the most favourable outcomemea-
sure of the study, that is, onlymeasureswhere signi¢cant
di¡erences are detected.
CONCLUSION
Despite the fact that cost^ e¡ectiveness studies of ICS
for the treatment of asthma still su¡er from shortcom-
ings in the outcomesmeasures used, adherence to analy-
tical standards has increased over time. However, our
review revealed shortcomings in methods for costing,
design of the study ingeneral andmethods for comparing
doses in particular.The choice of dosesmay cause bias in
the cost^ e¡ectiveness results and is therefore a threat
to the validity when evaluating competing therapies.
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